Opthea cut to Market Perform at Leerink on failed sozinibercept trial
Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12. The firm cites the company ...
pharmaphorum5d
Phase 3 readout puts Opthea at risk of insolvency
Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.
Fierce Biotech5d
Opthea's eye disease drug defeated by Eylea in phase 3, leaving biotech to mull future
Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...